Stock 300233 SHANDONG JINCHENG PHARMACEUTICAL GROUP CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shandong Jincheng Pharmaceutical Group Co., Ltd

Equities

300233

CNE100001500

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
18.82 CNY +9.55% Intraday chart for Shandong Jincheng Pharmaceutical Group Co., Ltd +13.99% +12.97%
04-24 Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-29 Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023, Payable on May 8, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5,367 7,742 7,390 11,167 8,741 6,336
Enterprise Value (EV) 1 5,161 7,372 6,903 10,838 8,533 5,866
P/E ratio 20.4 x 38.2 x -15.1 x 104 x 32.1 x 37 x
Yield 1.83% 1.01% 1.06% 0.68% 0.66% 1.2%
Capitalization / Revenue 1.78 x 2.77 x 2.49 x 3.56 x 2.49 x 1.79 x
EV / Revenue 1.72 x 2.64 x 2.33 x 3.45 x 2.43 x 1.66 x
EV / EBITDA 8 x 12.1 x 13.1 x 24.5 x 13.7 x 11.2 x
EV / FCF -3,242 x 31.6 x 28.7 x 1,121 x 74 x 23.3 x
FCF Yield -0.03% 3.16% 3.48% 0.09% 1.35% 4.28%
Price to Book 1.34 x 1.9 x 2.15 x 3.29 x 2.42 x 1.72 x
Nbr of stocks (in thousands) 393,152 390,026 387,903 383,875 383,875 380,338
Reference price 2 13.65 19.85 19.05 29.09 22.77 16.66
Announcement Date 28/03/19 20/04/20 26/04/21 24/03/22 30/03/23 28/03/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 3,008 2,795 2,962 3,138 3,506 3,538
EBITDA 1 645.1 608.3 526.7 443.2 624.7 525.4
EBIT 1 475.7 429.2 328.7 224 373.3 220
Operating Margin 15.81% 15.36% 11.1% 7.14% 10.65% 6.22%
Earnings before Tax (EBT) 1 370.1 315.2 -425.4 196.6 346 225.4
Net income 1 263.9 203.3 -488.8 108 273.4 174.7
Net margin 8.77% 7.27% -16.5% 3.44% 7.8% 4.94%
EPS 2 0.6700 0.5200 -1.260 0.2800 0.7100 0.4500
Free Cash Flow 1 -1.592 233.2 240.6 9.671 115.3 251.2
FCF margin -0.05% 8.34% 8.12% 0.31% 3.29% 7.1%
FCF Conversion (EBITDA) - 38.34% 45.67% 2.18% 18.46% 47.81%
FCF Conversion (Net income) - 114.73% - 8.96% 42.19% 143.79%
Dividend per Share 2 0.2500 0.2000 0.2018 0.1982 0.1500 0.2000
Announcement Date 28/03/19 20/04/20 26/04/21 24/03/22 30/03/23 28/03/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 205 370 487 329 208 471
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.59 233 241 9.67 115 251
ROE (net income / shareholders' equity) 7.04% 5.24% -12.7% 3.56% 8.05% 5.2%
ROA (Net income/ Total Assets) 5.83% 4.93% 3.88% 2.72% 4.2% 2.34%
Assets 1 4,522 4,123 -12,604 3,963 6,503 7,461
Book Value Per Share 2 10.20 10.40 8.870 8.840 9.420 9.680
Cash Flow per Share 2 1.840 2.540 2.780 2.560 2.240 2.670
Capex 1 350 362 272 376 374 343
Capex / Sales 11.63% 12.94% 9.2% 11.99% 10.66% 9.69%
Announcement Date 28/03/19 20/04/20 26/04/21 24/03/22 30/03/23 28/03/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANDONG JINCHENG PHARMACEUTICAL GROUP CO., LTD Stock Shandong Jincheng Pharmaceutical Group Co., Ltd
+12.97% 986M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300233 Stock
  4. Financials Shandong Jincheng Pharmaceutical Group Co., Ltd